Bayesian Capital Management’s Veracyte VCYT Stock Holding History

Bayesian Capital Management’s Portfolio VCYT Stock Details VCYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-17,500	Closed	-$693K	–	983
2024 Q4	$693K	Buy	+17,500	New	+$663K	0.08%	304
2023 Q4	–	Sell	-18,591	Closed	-$415K	–	1050
2023 Q3	$415K	Sell	18,591 -8,500	-31%	-$219K	0.05%	408
2023 Q2	$690K	Sell	27,091 -11,100	-29%	-$269K	0.07%	340
2023 Q1	$852K	Buy	38,191 +26,747	+234%	+$646K	0.11%	262
2022 Q4	$272K	Buy	+11,444	New	+$266K	0.04%	515
2022 Q2	–	Sell	-15,200	Closed	-$419K	–	1098
2022 Q1	$419K	Buy	+15,200	New	+$435K	0.06%	429
2021 Q2	–	Sell	-3,800	Closed	-$204K	–	655
2021 Q1	$204K	Buy	+3,800	New	+$219K	0.05%	457
2019 Q2	–	Sell	-11,324	Closed	-$283K	–	685
2019 Q1	$283K	Sell	11,324 -3,200	-22%	-$61.1K	0.05%	397
2018 Q4	$183K	Buy	+14,524	New	+$172K	0.04%	526

Other funds holding VCYT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Bayesian Capital Management's VCYT Position: Q1 2025 in Review

Bayesian Capital Management sold out of Veracyte (VCYT) in Q1 2025, closing a stake of 17,500 shares — an estimated $693K sold.

Bayesian Capital Management first reported a position in VCYT in Q4 2018 and held it in 9 quarters. The position peaked at $852K in Q1 2023. 287 funds tracked by Wall St. Rank hold VCYT as of Q1 2025.

Bayesian Capital Management reported no remaining Veracyte position as of Q1 2025 after selling out during the quarter.
Bayesian Capital Management sold 17,500 Veracyte shares in Q1 2025, an estimated $693K.
Bayesian Capital Management first reported a position in Veracyte in Q4 2018 and held it in 9 quarters.
Bayesian Capital Management's Veracyte position peaked at $852K in Q1 2023.
287 funds tracked by Wall St. Rank held Veracyte as of Q1 2025.

Based on Bayesian Capital Management's 13F filing for Q1 2025, filed 15 May 2025.